炎症性肠病患者从阿达木单抗原研药转换为阿达木单抗生物类似药的现实世界结局:ADA-SWITCH研究
ADA-SWITCH研究纳入524例处于临床缓解的炎症性肠病患者,比较维持阿达木单抗原研药(非转换队列313例)与转换为阿达木单抗生物类似药(转换队列211例)的结局。转换队列中位随访13个月,非转换队列24个月(p < 0.001)。转换与原研药维持相比,治疗持续率、临床缓解及安全性结局均无显著差异。
要点
- 转换队列阿达木单抗停药发生率为每患者年8%,非转换队列为每患者年7%(p > 0.05)。
- 转换队列复发发生率为每患者年8%,非转换队列为每患者年6%(p > 0.05)。
- 转换队列6%患者发生不良事件,非转换队列为5%(p > 0.05)。
核心结论
- 转换为阿达木单抗生物类似药与维持原研药相比,未损害炎症性肠病患者的结局。
研究设计与样本
- 纳入标准剂量阿达木单抗原研药治疗且处于临床缓解的炎症性肠病患者,维持原研药者为非转换队列(313例),转换为不同阿达木单抗生物类似药者为转换队列(211例),共524例。
- 采用逆概率治疗加权比例风险Cox回归控制治疗停药的潜在混杂效应。
- 临床缓解定义为克罗恩病Harvey-Bradshaw指数≤4、溃疡性结肠炎部分Mayo评分≤2。
主要发现
- 转换队列中位随访13个月,非转换队列24个月(p < 0.001)。
- 阿达木单抗停药发生率在转换队列为每患者年8%,非转换队列为每患者年7%(p > 0.05)。
- 多因素分析中,从阿达木单抗原研药转换为生物类似药与治疗停药无关。
- 复发发生率在转换队列为每患者年8%,非转换队列为每患者年6%(p > 0.05)。
- 不良事件发生率在转换队列为6%,非转换队列为5%(p > 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained ADA originator vs. those who switched to ADA biosimilar. METHODS: Patients receiving ADA originator who were in clinical remission at standard dose of ADA originator were included. Patients who maintained ADA originator formed the non-switch cohort (NSC), and those who switched to different ADA biosimilars constituted the switch cohort (SC). Clinical remission was defined as a Harvey-Bradshaw index ≤4 in Crohn's disease and a partial Mayo score ≤2 in ulcerative colitis. To control possible confounding effects on treatment discontinuation, an inverse probability treatment weighted proportional hazard Cox regression was performed. RESULTS: Five hundred and twenty-four patients were included: 211 in the SC and 313 in the NSC. The median follow-up was 13 months in the SC and 24 months in the NSC (p < 0.001). The incidence rate of ADA discontinuation was 8% and 7% per patient-year in the SC and in the NSC, respectively (p > 0.05). In the multivariate analysis, switching from ADA originator to ADA biosimilar was not associated with therapy discontinuation. The incidence rate of relapse was 8% per patient-year in the SC and 6% per patient-year in the NSC (p > 0.05). Six percent of the patients had adverse events in the SC vs. 5% in the NSC (p > 0.05). CONCLUSION: Switching to ADA biosimilar did not impair patients' outcomes in comparison with maintaining on the originator.
引用
- Casanova MJ, Nantes Ó, Varela P, et al. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study. Aliment Pharmacol Ther. 2023. PMID: 37089065. doi:10.1111/apt.17525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。